Condition 1: uterine fibromas or leiomyomas. Condition 2: Abnormal uterine bleeding. Leiomyoma of uterus Abnormal uterine and vaginal bleeding, unspecified
Conditions
Interventions
Intervention 1: Intervention group: Group one will receive letrozole at a dose of 2.5 mg daily for three months. Intervention 2: Intervention group: Group two will receive cabergoline at a dose of 2.5
Sponsors
Tabriz University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
25 Years to 55 Years
Inclusion criteria
Inclusion criteria: Women aged 25 to menopause, defined as 1 year of consecutive absence of menstrual bleeding Uterine fibroids classified as FIGO types 2, 3, 4, and 5 with sizes ranging from 5 to 10 centimeters
Exclusion criteria
Exclusion criteria: Women in menopause, defined as 1 year of consecutive absence of menstrual bleeding, with symptoms of hypoestrogenism having uterine masses with diagnoses other than uterine leiomyoma or suspicion of sarcoma
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Dimensions and number of leiomyomas. Timepoint: Beginning and end of treatment. Method of measurement: Abdominal or vaginal ultrasound.;Clinical symptoms. Timepoint: Beginning and end of treatment. Method of measurement: Questionnaire. | — |
Secondary
| Measure | Time frame |
|---|---|
| Side effects of treatment. Timepoint: Beginning and end of treatment. Method of measurement: Questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactReza Sattarpour
Tabriz University of Medical Sciences
Outcome results
None listed